Traws Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Traws Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 1,135% in 3 years; of every extra $100 of sales, $1,097 became extra profit. Higher than 97% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 983% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$1,097Sales grew 1,135% in 3 years; of every extra $100 of sales, $1,097 became extra profit.
Higher than 97% of Healthcare companies in United States.
Asset Productivity Ratio
+1135% / -73%In 3 years sales changed by +1135% while total assets changed by -73%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
76%Of every $100 the company owns, $76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Traws Pharma, Inc. made a loss over the last year. Traws Pharma, Inc. owes $0.85 for every $1 it owns. Traws Pharma, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTraws Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.33The share price is 3.33 times Traws Pharma, Inc.'s book value per share, higher than 59% of Healthcare companies in United States.
Market cap
$6 MThe total market value of all of Traws Pharma, Inc.'s shares at today's price (share price × number of shares), smaller than 92% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat Traws Pharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.11Net worth divided by the number of shares. The share price of $0.37 is 3.3 times this, which is the P/B above.
Return on equity (ROE)
-433.4%Traws Pharma, Inc. lost 433.4% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
0.85×Traws Pharma, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NoneTraws Pharma, Inc. does not currently pay a dividend.
Revenue growth
+1135%Revenue rose 1135% in the year to Dec 2025, and grew 131% a year on average over 3 years.
Profit growth
Back to profitTraws Pharma, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
328.7%Traws Pharma, Inc. keeps $329 of every $100 of revenue as net profit.
Cash quality
-2.0×Cash from Traws Pharma, Inc.'s business was -2.0× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Traws Pharma, Inc.: $6 M ÷ $2 M (30 Jun 2026) = 3.3.
What is Traws Pharma, Inc.'s return on equity?
Traws Pharma, Inc. lost 433.4% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Traws Pharma, Inc. owe compared with what it owns?
Traws Pharma, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Traws Pharma, Inc. pay a dividend?
No. Traws Pharma, Inc. does not currently pay a dividend.
Is Traws Pharma, Inc.'s revenue growing?
Revenue rose 1135% in the year to Dec 2025, and grew 131% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.